- In December 2024, Torrent Pharmaceuticals has announced an agreement to acquire three anti-diabetes brands from Boehringer Ingelheim International GmbH (BI). This acquisition will enable Torrent to enhance its portfolio in the diabetes care market, allowing the company to broaden its therapeutic offerings and expand its reach in a rapidly growing global market
